A complete versus inducible ischemia-guided revascularization after a culprit-only primary percutaneous coronary intervention in multivessel coronary artery disease – a pilot study

1Dedinje Institute for cardiovascular diseases, Department of interventional cardiology, Belgrade, Serbia; 2Zemun Clinical Hospital Centre, Department of cardiology, Belgrade, Serbia; 3University of Belgrade, Faculty of Medicine, Belgrade, Serbia

Received: March 15, 2020
Accepted: November 14, 2020
Online First: November 17, 2020
DOI: https://doi.org/10.2298/SARH200315108I

*Accepted papers* are articles in press that have gone through due peer review process and have been accepted for publication by the Editorial Board of the *Serbian Archives of Medicine*. They have not yet been copy-edited and/or formatted in the publication house style, and the text may be changed before the final publication.

Although accepted papers do not yet have all the accompanying bibliographic details available, they can already be cited using the year of online publication and the DOI, as follows: the author’s last name and initial of the first name, article title, journal title, online first publication month and year, and the DOI; e.g.: Petrović P, Jovanović J. The title of the article. Srp Arh Celok Lek. Online First, February 2017.

When the final article is assigned to volumes/issues of the journal, the Article in Press version will be removed and the final version will appear in the associated published volumes/issues of the journal. The date the article was made available online first will be carried over.

*Correspondence to:*
Ivan Ilić
Department of interventional cardiology, Institute for cardiovascular diseases Dedinje Heroja Milana Tepica 1, 11040 Belgrade, Serbia
E-mail: ivanilic@yahoo.com
A complete versus inducible ischemia-guided revascularization after a culprit-only primary percutaneous coronary intervention in multivessel coronary artery disease – a pilot study

Summary
Introduction/Objective Revascularization in multivessel coronary artery disease (MVD) in patients with ST elevation myocardial infarction (STEMI) is a matter of debate. We sought to compare outcomes between revascularization strategies based on angiographic lesion severity or inducible ischemia.

Methods In prospective study, first ever STEMI patients with MVD, defined as > 70% stenosis in non-culprit vessel, treated with culprit only primary PCI were randomized to: A. Complete revascularization of all non-culprit significant lesions during initial hospitalization; B. Complete revascularization after 30 days, or C. Revascularization based on non-invasive testing for inducible ischemia. The study explored occurrence of major adverse cardio-cerebral events (MACCE) (cardiac death, repeated MI, cerebrovascular event).

Results The study enrolled 120 patients with door to balloon time within appropriate limits (A 51 ± 26 vs. B 47 ± 33 vs. C 44 ± 29 min, p = 0.604). The patients in group A underwent complete revascularization at 6 [4–7] days after primary PCI, while in the group B it was 35 [32–39] days. In group C 16/43 (37.2%) patients underwent PCI at 82 [66–147] days after infarction (p < 0.001). The patients were followed for 2.7 ± 0.8 years. The events occurred less frequently in patients that underwent planned complete revascularization compared to those who underwent ischemia testing (7.8 vs. 20.9%, p = 0.040). Kaplan-Meier analysis favored complete delayed revascularization (MACCE A 8.8 vs. B 6.9 vs. C 20.9%, log rank p = 0.041).

Conclusions Planned, angiography guided, complete revascularization after initial event may be favorable strategy compared to single stress test for multivessel coronary artery disease in STEMI.

Keywords: Coronary Artery Disease; Myocardial Infarction; Echocardiography, stress

Summary
Увод/Циљ Реваскуларизација у вишесудовној коронарној болести (МВД) код пацијената са инфаркт миокарда са ST елевацијом (STEMI) је изазов. Упоредили смо клиничке исходе између различитих стратегија реваскуларизације руковођене ангиографски процењеним степеном судовних стеноза или на основу стресс ехокардиографије.

Методе У проспективном истраживању, пацијенти са првим STEMI епизодом и МВД, који су подвргнути комплетној реваскуларизацији свих лезија током иницијалне хоспитализације; Б. комплетну реваскуларизацију након 30 дана; В. Реваскуларизацију на основу провокабилних исхемија. Студија је бележила наставак нежељених догађаја након прве епизоде миокардног инфаркта, цереброваскуларних догађаја – срчане смрти, поново утицаја на исхемију."}

Резултати Укључено је 120 пацијената код којих је време до реперфузије било у границама препоручених вредности (А 51 ± 26 vs. Б 47 ± 33 vs. В 44 ± 29 минута, p = 0.604). Пацијенти у групи А су подвргнути комплетној реваскуларизацији 6 (4–7) дана након прве епизоде PI; односно у групи Б реваскуларизован након 35 (32–39) дана. У групи В, 16/43 (37,2%) пацијената је подвргнуто PI након 82 (66–147) дана од инфаркта (p < 0.001). Пацијенти су праћени током 2,7 ± 0,8 година. Нежељених догађаја је било мање код пацијената који су подвргнути комплетној реваскуларизацији у односу на тестиране на исхемију (7,8 vs. 20,9%, p = 0.040). Каплан-Мејеровом анализом показана је предност комплетне реваскуларизације у току иницијалне хоспитализације (MACCE A 8,8 vs. Б 6,9 vs. В 20,9%, log rank p = 0.041).

Закључак Планирана, ангографски вођена комплетна реваскуларизација, након прве епизоде PI, може бити боља стратегија у односу на појединачно тестирање на исхемију код вишесудових коронарних болести.

Кључне речи: Коронарна болест, Инфаркт миокарда, Стрес ехокардиографија
INTRODUCTION

The multivessel coronary artery disease (MVD) is a common finding in patients presenting with ST elevation myocardial infarction (STEMI). It is estimated that around 40-50% of patients with STEMI present with MVD [1]. Previously, culprit only primary percutaneous coronary intervention (PCI) was indicated, but this was challenged by several studies suggesting benefits of immediate, complete revascularization at initial PCI or during initial hospitalization [2-4]. Although these studies enrolled relatively small number of participants with heterogeneous definition of MVD and composite end points, their results have caused important concern regarding the need for complete revascularization in patients with STEMI and MVD. Based on their results, guidelines for treatment of STEMI have been updated [5]. An observational, retrospective study has demonstrated benefit of staged PCI within 60 days of index intervention [6]. The strategy of dobutamine stress echocardiography testing after myocardial infarction seems feasible and safe and can predict serious adverse events during short term follow up [7].

We sought to investigate the appropriateness of staged, complete revascularization during hospitalization or after 30 days from initial PCI based on angiographic lesion severity compared to intervention based on outpatient non-invasive ischemia testing, aiming to reduce major adverse cardio-cerebral events (MACCE).

METHODS

This study was prospective, randomized, single center, open label study in patients with STEMI with multivessel coronary artery disease, initially treated with culprit only primary PCI. After successful culprit only primary PCI, patients were randomly assigned to one of three treatment arms: staged, complete revascularization of all non-culprit significant lesions in a single session during initial hospitalization; staged, complete revascularization of all
non-culprit significant lesions in a single session after 30 days from initial hospitalization for STEMI and revascularization or deferral of revascularization of non-culprit coronary artery lesions based on ischemia testing using dobutamine stress echocardiography. The study was approved by the institutional ethics committee and was done in accordance with Helsinki declaration (Clinical trials identifier: NCT 02756000).

**Patient population**

All patients admitted with clinical and electrocardiographic signs of first ever ST elevation myocardial infarction (chest pain lasting less than 12 hours with persistent ST elevation of $\geq 1\text{mm}$ in two contiguous leads on ECG recording) and MVD on initial coronary angiogram, defined as visually assessed stenosis of more than 70% of any of the non-culprit vessels, were treated with primary PCI of infarct related artery (IRA) only. Within 24h after completion of primary PCI, after obtaining a written informed consent, they were randomly assigned 1:1:1 to one of the treatment arms. The hemodynamically unstable patients, defined as presence of Killip class IV, need for mechanical circulatory support and/or ventilation prior, during and after primary PCI, presence of significant valvular disease or decision that patient needs to be treated with coronary artery bypass grafting (CABG) and/or valvular replacement or reconstruction surgery after initial culprit only PCI were not considered for the study. Patient were excluded from the study if myocardial infarction was caused by stent thrombosis or there was a chronic total occlusion of any of the coronary arteries on initial angiogram. Patients previously treated by CABG or having estimated life expectancy less than one year were also excluded from the study. Patients unsuitable for dobutamine stress echocardiography because of poor acoustic windows were also excluded from the study.
Randomization

Patients were randomized in a 1:1:1 fashion to one of the treatment arms according to computer generated algorithm (GraphPad Software, Inc., San Diego, California, US) after completion of primary PCI and signed informed consent form. Crossover between treatment arms was allowed only in case of persistent chest pain or patient’s hemodynamic instability that requires immediate coronary angiography and/or intervention that was further acknowledged as study endpoint. Vascular access, PCI technique, use of guiding catheters, coronary guidewires, thrombus aspiration, predilatation and stent implantation were used according to operators' preference, both at primary PCI and at repeated intervention.

Medical treatment

After establishing diagnosis of STEMI, patients were pre-treated with loading dose of aspirin (300 mg) and ticagrelor (180mg) or clopidogrel (600mg), while heparin (80-100IU/kg iv.), was given before insertion of coronary guidewire. After PCI aspirin, 100mg per day, was given indefinitely with ticagrelor 90mg twice a day or clopidogrel, 75mg per day. Recommended duration of dual antiplatelet therapy was 12 months. Patients were treated with beta blocking agents, ACE inhibitors and statins according to the current guidelines for STEMI [5].

Patients were seen in an office visit one month after final PCI or Dobutamine stress echocardiography – vital and clinical status along with prescribed medications were assessed, ECG and arterial blood pressure measurement done. Angina status assessment was done according to the Canadian Cardiovascular Society (CCS) Classification of angina or Braunwald angina classification.

Vital and clinical status, presence of angina, medications, hospitalization for any reason, myocardial infarction, repeated PCI or CABG were assessed at one year after initial
Dobutamine stress echocardiography

Dobutamine stress echocardiography (DSE) was performed in all stable patients assigned to this study arm at least 30 days after the coronary event according to the guidelines. In patients with suboptimal parasternal echo windows, the test was considered valid for interpretation if all apical views are obtained and suitable for analysis. The test was considered positive for inducible ischemia in the presence of new or worsening wall motion abnormalities in two or more adjacent segments [8].

Definitions

A culprit artery was defined as an artery with an identifiable thrombus and/or significant lesion on angiogram corresponding to ischemic ECG changes. Significant lesion was defined as coronary artery stenosis with narrowing of the lumen of more than 70% assessed by quantitative coronary angiography (QCA) software (Leonardo multimodality workstation, Siemens, Erlangen, Germany).

A repeated revascularization was considered clinically indicated if angiography during follow-up showed a diameter stenosis greater than or equal to 50 percent at any point in the coronary artery previously treated and if one of the following occurred: 1) a positive history of recurrent angina pectoris, presumably related to the target vessel; 2) objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel; 3) abnormal results of any functional diagnostic test (e.g. stress echocardiography, fractional flow reserve); 4) a revascularization with a diameter stenosis greater than 70% even in the absence of the above-mentioned ischemic signs or symptoms.

Death was regarded as cardiac in origin unless obvious non-cardiac causes could be
identified. Any death during the index hospitalization for STEMI was regarded as cardiac death. Sudden death was defined as unexplained death in previously stable patients. Myocardial infarction (MI) is defined according to the Fourth universal definition of myocardial infarction [9]. Procedure-related MI is regarded as present with creatinine kinase (CK) MB fraction ≥3 times upper limit of normal after PCI procedure or total CK ≥3 times upper limit of normal in the absence of CKMB measurement. Bleeding is defined according to the Bleeding Associated Research Consortium criteria [10].

Cerebrovascular accident was defined as sudden onset of vertigo, numbness, aphasia, or dysarthria due to vascular lesions of the brain such as hemorrhage, embolism, thrombosis, or rupturing aneurysm that persists > 24 hours.

Statistical analysis

Categorical variables were presented as numbers and percentages and were compared using chi square test. Continuous variables were expressed as mean ± standard deviation (SD) or medians with interquartile ranges. Continuous variables were compared using the one-way ANOVA or Kruskal Wallis’ test based on their distributions. Clinical outcomes were analyzed according to the intention-to-treat principle. Each endpoint was assessed by the Kaplan-Meier method and compared by log-rank test. Statistical analysis was done using IBM SPSS Statistics 20.0 software (IBM Corp. Armonk, New York, US). A p value of <0.05 was regarded as statistically significant.

RESULTS

The study included 120 patients in Clinical Hospital Centre Zemun, high volume university PCI center from June 2016 to January 2019. The study was prematurely stopped due to slow enrollment and after interim analysis revealed a potential futility in the ischemia-
testing arm of the study. The 182 patients were evaluated for the study after meeting the inclusion criteria. Due to poor acoustic window 21 patients (11.5%) could not be randomized to stress echocardiography, 14 patients (7.7%) have not signed an informed consent form to participate in the study, and surgical revascularization was recommended in 27 patients (14.8%).

The patients included in the study had high incidence of hypertension, dyslipidemia, and smoking. There was borderline difference in body mass index (BMI) between the groups (Table 1). Three-vessel disease was seen in over 40% patients in the group of patients randomized to complete revascularization during initial admission, which was higher incidence than in other groups, but the difference was insignificant. Thrombus aspiration was used as a first intervention in only 1/4 to 1/3 of patients while the balloon angioplasty was used in more than half of patients in all groups. The interventions were deemed successful in almost all patients with restoration of TIMI III flow (Table 2).

The patients randomized to complete revascularization during initial hospitalization underwent the procedure at a median of 6 [4 - 7] days after primary PCI, while the median time to complete PCI was 35 [32 - 39] days in a group randomized to staged intervention. In ischemia testing group patients underwent dobutamine stress echocardiography at 36 [31 - 46] days after initial admission for STEMI. Of these patients 16/43 (37.2%) were treated with PCI based on positive test results at the median of 82 [66 - 147] days after infarction (p<0.001). All patients with positive stress test result were treated with PCI of the non-culprit vessels, according to the study protocol.

The patients were followed for median of 1046 [734 - 1220] days and the adverse events occurred infrequently in all groups. The incidence of stable angina class CCS II and higher was similar in all study groups (group I 1/34, group II 3/43, group III 3/43, p = 0.137). Kaplan – Meier freedom from angina curves demonstrated relatively late onset of angina,
similar in all study groups (log rank p=0.309) (Figure 1). The MACCE events occurred more frequently in patients assigned to ischemia testing after initial culprit only primary PCI (table 3). Adverse cardiovascular events occurred less frequently in patients that underwent planned revascularization either at the initial hospitalization or after 30 days from initial primary PCI, compared to those who underwent ischemia testing (7.8 vs. 20.9%, p=0.040). Kaplan-Meier survival analysis favored complete delayed revascularization (log rank p=0.041) (Figure 2).

**DISCUSSION**

This pilot randomized study, done in a single, high volume PCI university center, has demonstrated that strategy based on single dobutamine stress echocardiography test to detect ischemia in non-culprit vessels territory after culprit only primary PCI was associated with increased incidence of adverse cardiovascular events compared to complete staged, angiography guided revascularization after primary PCI for first ever ST elevation myocardial infarction in patients with multivessel coronary artery disease during long term follow up.

The decision when to do staged PCI after primary PCI can be affected by many factors. A prothrombotic and inflammatory milieu related to possible stent thrombosis, large myocardial territory at risk with multivessel PCI in STEMI along with the procedural risks (increased radiation and contrast load) can all lead to decreased benefit of immediate complete revascularization [11, 12]. In addition, an estimate of severity of the non-culprit lesions could be jeopardized by spasm of the entire coronary tree leading to unnecessary PCI procedures [13]. Older age, overt heart failure, decreased renal function and additional medical conditions requiring attention can be the reasons to avoid complete revascularization during initial hospitalization that could translate to increased incidence of adverse events [14, 15]. The staged PCI for STEMI can be beneficial compared to culprit only PCI as Cui and al.
has showed in retrospective analysis of more than 1000 patients. The staged procedure was
done within 30 days of primary PCI and after propensity matching of patients, had lower
incidence of MACCE. However, the same study failed to demonstrate the benefit of this
strategy for diabetic patients [16]. The registry by Hannah et al. has demonstrated a benefit in
terms of reduced mortality at 12 months for staged PCI within 60 days after initial primary
PCI compared to culprit only PCI within the initial hospitalization. The study also
demonstrated increased in-hospital mortality for multivessel PCI at the initial procedure [6].
Recently published large trial that included more than 4000 patients has demonstrated
consistent benefit of complete revascularization in MVD patients with STEMI compared to
culprit only primary PCI during long term follow up. The complete revascularization was
done either during initial hospitalization or within 45 days from initial event [17]. A large
Korean registry data also supported the strategy of delayed complete revascularization during
initial hospitalization in MVD [18]. The findings in our study support complete
revascularization at initial hospitalization or after 30 days based on lesion severity assessed at
initial coronary angiogram, showing reduced incidence of MACCE.

The strategy based on non-invasive ischemia testing, in our study, was associated with
increased incidence of MACCE. Kaplan Meier curves separate late in the follow up, when
there was higher incidence of events in the ischemia testing group. The reason for this could
be the progression of atherosclerotic disease that was not detected as significant ischemia
burden on the early dobutamine stress echocardiographic study. Atherosclerosis is a
progressive disease and it has been demonstrated that patients that suffered an event would
have high incidence of repeated events despite the revascularization and medical treatment
[19]. Also, stress testing after revascularization usually yields very few repeated
revascularization procedures irrespective of the test results [20]. However, positive test
results in terms of inducible ischemia usually are related to increased incidence of adverse
events. In the meta-analysis by Harb et al., that analyzed the studies where stress echocardiography was used to detect ischemia after revascularization, it has been demonstrated that inducible ischemia was associated with increased incidence of adverse cardiovascular events. This study pointed out that older age and time interval between initial revascularization and the positive stress test were predictors of worse outcomes, meaning that longer the time interval between the revascularization and the test, more adverse events occurred. The authors stressed that the impact of time interval was caused by progression of coronary artery disease and more events occurring during longer follow up period [21]. The study by Sicari et al., has pointed out that early stress test after MI could be helpful in predicting adverse events during short term follow up, up to one year, but thereafter progression of atherosclerotic disease in a non-culprit vessels may provoke new ischemic events, as shown in large Swedish registry of patients with MI undergoing culprit only primary PCI [8, 22]. Patients in our study underwent stress echocardiography early after initial event and additional tests were not planned, so the higher incidence of events was probably due to further progression of atherosclerosis and/or restenosis of previously treated lesions. Late onset of angina as a sign of progressing atherosclerosis, long after the test was done, further supports the idea that the higher rate of MACCE events in the ischemia-testing group was due to progression of atherosclerotic lesions that, albeit present, did not provoke myocardial ischemia at the time of the test. Also, stress tests in asymptomatic patients yield few repeated revascularization procedures, a fact that had to be accounted for [23]. On the other hand, in other two groups we might have treated with PCI some intermediate lesions that were not physiologically significant or causing ischemia, despite perceived as significant on coronary angiogram. Due to small cohort of patients the benefits of such treatment probably exceeded the potential “costs” in terms of complications and restenosis [24, 25].

How to treat MVD patient after primary PCI in STEMI remains an open question.
Complete revascularization based on angiographic estimate of stenosis severity has proven benefits but comes with a risk of unnecessary interventions producing more restenosis and stent thrombosis. A strategy of repeated noninvasive ischemia testing after initial revascularization may discern between the patients deemed for revascularization and the ones who should be treated medically avoiding the risks of inappropriate invasive procedures. The timing and the interval between repeated test need to be investigated further.

**Study limitation**

The study included small number of selected patients (first ever myocardial infarction in native coronary artery, no CTO, preserved LVEF, good echocardiographic windows) with MVD and STEMI, therefore its conclusions may not be applicable to general population. In the study we used dobutamine stress echocardiography to assess ischemia. This test with its inherent limitations in detecting ischemia may influence decisions to perform further revascularization.

**CONCLUSION**

The ischemia guided strategy based on early single dobutamine stress echocardiography test may be inferior to complete revascularization based on angiographic estimate of stenosis severity in multivessel disease patient within thirty days after primary PCI for first ever ST elevation myocardial infarction. The repeated testing may improve detection of atherosclerosis progression and allow institution of appropriate treatment.

**Conflict of interests:** None declared.
REFERENCES

1. Sorajja P, Gersh BJ, Cox DA, McLaughlin MG, Zimetbaum P, Costantini C, et al. Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. Eur Heart J. 2007;28:1709-1716. doi: 10.1093/eurheartj/ehm184.PMID: 17556348

2. Wald DS, Morris JK, Wald NJ, Chase AJ, Edwards RJ, Hughes LO, et al; PRAMI Investigators. Randomized trial of preventive angioplasty in myocardial infarction. N Engl J Med. 2013;369:1115-1123. PMID: 23991625 DOI: 10.1056/NEJMoa1305520

3. Gershlick AH, Banning AS, Parker E, Wang D, Budgeon CA, Kelly DJ, et al. Long-Term Follow-Up of Complete Versus Lesion-Only Revascularization in STEMI and Multivessel Disease: The CvLPRIT Trial. J Am Coll Cardiol. 2019;74:3083-3094. doi: 10.1016/j.jacc.2019.10.033.PMID: 31856964

4. Engstrøm T, Kelbæk H, Helqvist S, Høfsten DE, Kløvgaard L, Holmvang L, et al; DANAMI-3—PRIMULTI Investigators. Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3—PRIMULTI): an open-label, randomised controlled trial. Lancet. 2015;386:665-71. doi: 10.1016/s0140-6736(15)60648-1.PMID: 26347918

5. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al; ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39:119-177. doi: 10.1093/eurheartj/ehx393.PMID: 28886621

6. Hannan EL, Samadashvili Z, Walford G, Holmes DR Jr, Jacobs AK, Stamato NJ, et al. Culprit vessel percutaneous coronary intervention versus multivessel and staged percutaneous coronary intervention for ST-segment elevation myocardial infarction patients with multivessel disease. JACC Cardiovasc Interv. 2010;3:22-31. doi: 10.1097/MLR.0000000000000520.PMID: 27078825
7. Sicari R, Picano E, Landi P, Pasanisi E, Venneri L. Pharmacologic stress echocardiography predicts total mortality early after acute myocardial infarction. J Am Soc Echocardiogr. 2004;17:114–120. doi: 10.1053/euhj.2001.3072. PMID: 12093055

8. Pellikka PA, Arruda-Olson A, Chaudhry FA, Chen MH, Marshall JE, Porter TR, et al. Guidelines for Performance, Interpretation, and Application of Stress Echocardiography in Ischemic Heart Disease: From the American Society of Echocardiography. J Am Soc Echocardiogr. 2020;33:1-41.e8. doi: 10.1016/j.echo.2019.07.001. PMID: 31740370

9. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al; Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction. Fourth Universal Definition of Myocardial Infarction. J Am Coll Cardiol 2018;72:2231–2264. DOI: 10.1016/j.jacc.2018.08.1038. PMID: 30153967.

10. Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. Eur Heart J. 2019;40:2632-2653. doi: 10.1093/eurheartj/ehz372. PMID: 31116395

11. Chan MY, Andreotti F, Becker RC. Hypercoagulable states in cardiovascular disease. Circulation.2008;118:2286–2297. DOI: 10.1161/CIRCULATIONAHA.108.778837. PMID: 19029477.

12. Kereiakes DJ, Gurbel PA. Peri-procedural platelet function antiplatelet inhibition in percutaneous coronary intervention. J Am Coll Cardiol Intv 2008;1:111–121. doi: 10.1016/j.jcin.2008.01.005. PMID: 19463287

13. Hanratty CG, Koyama Y, Rasmussen HH, Nelson GIC, Hansen PS, Ward MR. Exaggeration of nonculprit stenosis during acute myocardial infarction: implication for immediate multivessel revascularization. J Am Coll Cardiol. 2002;40:911–916. doi: 10.1016/s0735-1097(02)02049-1. PMID: 12225715
14. Burgess SN, French JK, Nguyen TL, Leung M, Richards DAB, Thomas L, et al. The impact of incomplete revascularization on early and late outcomes in ST-elevation myocardial infarction. Am Heart J. 2018;205:31-41. PMID: 30153623. DOI: 10.1016/j.ahj.2018.07.017

15. Rumiz E, Berenguer A, Vilar JV, Valero E, Facila L, Cubillos A, et al. Long-term outcomes and predictors of morbi-mortality according to age in STEMI patients with multivessel disease: Impact of an incomplete revascularization. Catheter Cardiovasc Interv. 2018;92:E512-E517. PMID: 30019820. DOI: 10.1002/ccd.27691

16. Cui K, Lyu S, Song X, Liu H, Yuan F, Xu F, et al. Long-Term Safety and Efficacy of Staged Percutaneous Coronary Intervention for Patients with ST-Segment Elevation Myocardial Infarction and Multivessel Coronary Disease. Am J Cardiol. 2018;122:1670-1676. doi: 10.1016/j.amjcard.2019.04.048. PMID: 31174834

17. Mehta SR, Wood DA, Storey RF, Mehran R, Bainey KR, Nguyen H, et al; COMPLETE Trial Steering Committee and Investigators. Complete Revascularization with Multivessel PCI for Myocardial Infarction. N Engl J Med. 2019;381:1411-1421. doi: 10.1056/NEJMoa1907775. PMID: 31475795.

18. Kim MC, Bae S, Ahn Y, Sim DS, Hong YJ, Kim JH, et al. Korea Acute Myocardial Infarction Registry Investigators. Benefit of a staged in-hospital revascularization strategy in hemodynamically stable patients with ST-segment elevation myocardial infarction and multivessel disease: Analyses by risk stratification. Catheter Cardiovasc Interv. 2020 Jun 22. doi: 10.1002/ccd.29062. Online ahead of print. PMID: 32569397

19. Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J. 2015;36:1163-1170. doi: 10.1093/eurheartj/ehu505. PMID: 25586123

20. Mudrick DW, Shah BR, McCoy LA, Lytle BL, Masoudi FA, Federspiel JJ, et al. Patterns of stress testing and diagnostic catheterization after coronary stenting in 250 350 Medicare beneficiaries. Circ Cardiovasc Imaging. 2013; 6:11–19. doi: 10.1016/j.jacc.2010.03.093. PMID: 20888523
21. Harb SC, Marwick TH. Prognostic value of stress imaging after revascularization: a systematic review of stress echocardiography and stress nuclear imaging. Am Heart J. 2014;167:77-85. doi: 10.1016/j.ahj.2013.07.035. PMID: 24332145

22. Varenhorst C, Hasvold P, Johansson S, Janzon M, Albertsson, P, Leosdottir M, et al. Culprit and Nonculprit Recurrent Ischemic Events in Patients With Myocardial Infarction: Data From SWEDHEART (Swedish Web System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies). J Am Heart Assoc. 2018;7: e007174. PMID: 31913732 DOI: 10.1161/JAHA.117.007174.

23. Peterson T, Wells Askew J, Bell M, Crusan D, Hodge D, Gibbons RJ. Low yield of stress imaging in a population-based study of asymptomatic patients after percutaneous coronary intervention. Circ Cardiovasc Imaging. 2014;7:438-445. PMID: 24687040 DOI: 10.1161/CIRCIMAGING.113.000833.

24. Zimmermann FM, Ferrara A, Johnson NP, van Nunen LX, Escaned J, Albertsson P, et al. Deferral vs. performance of percutaneous coronary intervention of functionally non-significant coronary stenosis: 15-year follow-up of the DEFER trial. Eur Heart J. 2015;36:3182-3188. PMID: 26400825 DOI: 10.1093/eurheartj/ehv452.

25. Xaplanteris P, Fournier S, Pijls NHJ, Fearon WF, Barbato E, Tonino PAL, et al; FAME 2 Investigators. Five-Year Outcomes with PCI Guided by Fractional Flow Reserve. N Engl J Med. 2018;379:250-259. DOI: 10.1056/NEJMoa1803538. PMID: 29785878
Table 1. Clinical characteristics of the patients in the study groups

| Variable            | In hospital (n = 34) | After 30 days (n = 43) | Ischemia testing (n = 43) | p   |
|---------------------|----------------------|------------------------|---------------------------|-----|
| Age (years)         | 61 ± 8               | 60 ± 11                | 60 ± 9                    | 0.877|
| Male gender (%)     | 70.6                 | 74.4                   | 65.1                      | 0.640|
| Heredity (%)        | 41.1                 | 44.2                   | 44.2                      | 0.956|
| Smoking (%)         | 44.1                 | 53.5                   | 65.1                      | 0.179|
| Hypertension (%)    | 79.4                 | 72.1                   | 83.7                      | 0.418|
| Dyslipidemia (%)    | 52.9                 | 55.8                   | 69.7                      | 0.255|
| Diabetes mellitus (%) | 23.5               | 32.5                   | 21.0                      | 0.439|
| PAD (%)             | 0.0                  | 4.6                    | 2.3                       | 0.429|
| CKD (%)             | 2.9                  | 2.3                    | 4.6                       | 0.826|
| COPD (%)            | 8.8                  | 7.0                    | 7.0                       | 0.942|
| BMI (kg/m²)         | 29 ± 4               | 27 ± 4                 | 27 ± 4                    | 0.047|
| LVEF (%)            | 43 ± 7               | 43 ± 8                 | 45 ± 7                    | 0.963|

BMI – body mass index; CKD – chronic kidney disease; COPD – chronic obstructive pulmonary disease; LVEF – left ventricular ejection fraction; PAD – peripheral arterial disease.
**Table 2.** Primary PCI characteristics in the study groups

| Variable                        | In hospital (n = 34) | After 30 days (n = 43) | Ischemia testing (n = 43) | p   |
|---------------------------------|----------------------|-------------------------|---------------------------|-----|
| Prehospital time (min)          |                      |                         |                           |     |
|                                 | 295 ± 199            | 225 ± 196               | 241 ± 220                 | 0.531|
| D2B time (min)                  | 51 ± 26              | 47 ± 33                 | 44 ± 29                   | 0.604|
| Radial access (%)               | 55.9                 | 51.2                    | 46.5                      | 0.715|
| Triple vessel disease (%)       | 41.2                 | 23.2                    | 23.2                      | 0.146|
| LAD culprit (%)                 | 41.2                 | 37.2                    | 30.3                      | 0.593|
| Cx culprit (%)                  | 17.6                 | 18.6                    | 13.9                      | 0.832|
| RCA culprit (%)                 | 41.2                 | 44.2                    | 55.8                      | 0.382|
| Thrombus aspiration (%)         | 35.3                 | 25.6                    | 25.6                      | 0.568|
| Predilatation (%)               | 50.0                 | 65.1                    | 60.4                      | 0.398|
| GP IIbIIIa inhibitor (%)        | 20.6                 | 18.6                    | 20.9                      | 0.959|
| Total contrast load (ml)        | 157 ± 71             | 156 ± 63                | 153 ± 42                  | 0.963|
| TIMI III flow (%)               | 100                  | 97.7                    | 97.7                      | 0.669|

Cx – circumflex artery; D2B – door to balloon time; GP – glycoprotein; LAD – left anterior descending; RCA – right coronary artery; TIMI – thrombolysis in myocardial infarction
**Table 3.** Incidence of MACCE events in the study groups

| Variable            | In hospital (n = 34) | After 30 days (n = 43) | Ischemia testing (n = 43) |
|---------------------|----------------------|-------------------------|--------------------------|
| Death, n (%)        | 0 (0.0)              | 0 (0.0)                 | 2 (4.6)                  |
| Repeated MI, n (%)  | 1 (2.9)              | 1 (2.3)                 | 2 (4.6)                  |
| Repeated PCI, n (%) | 2 (5.9)              | 2 (4.6)                 | 4 (9.2)                  |
| CVI, n (%)          | 0 (0.0)              | 0 (0.0)                 | 4 (9.2)                  |
| MACCE, n (%)        | 3 (8.8)              | 3 (6.9)                 | 9 (20.9)                 |

CVI – cerebrovascular insult; MI – myocardial infarction; PCI – percutaneous coronary intervention; MACCE – major adverse cardio-cerebral event
Figure 1. Kaplan Meier plot representing freedom from angina CCS II during follow up in days after initial event (study groups A – immediate complete revascularization; B – delayed complete revascularization; C – revascularization based on stress-echocardiography)
Figure 2. Kaplan Meier plot representing freedom from major adverse cardio-cerebral events (MACCE) during follow up in days (study groups A – immediate complete revascularization; B – delayed complete revascularization; C – revascularization based on stress-echocardiography result)